CTRI/2023/10/058630招募中3 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Subcutaneously to Healthy Subjects Aged 4 to 60 Years in India - NI
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects aged =4 to =60 years at the time of random assignment.
- •2. Male or female.
- •3. Subjects in good health at the time of entry into the trial.
- •4. Subjects and/or the subjects legally acceptable representative (LAR) who have signed and dated a written, informed consent/pediatric assent form, and any required privacy authorization prior to the initiation of any trial procedures.
- •5. Subjects who can comply with trial procedures and are available for the duration of follow-up
排除标准
- •1.Subjects with any illness, or history of any illness that in the opinion of the investigator, might interfere with the results of the trial or pose an additional risk to the subject due to participation in the trial
- •2.Behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject’s ability to participate in the trial.
- •3.BMI =35 kg/m2
- •4.Intent to participate in another clinical trial at any time during the conduct of this trial
- •5.Subject plans to receive any of the following (consider whether applicable as an exclusion criterion or as a criterion for delay of Visit 1):
- •a)A licensed vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to TDV or placebo administration.
- •b)A coronavirus vaccine within 14 days prior to TDV or placebo administration.
- •c)A vaccine authorized for emergency use within 28 days of TDV or placebo administration.
- •6.Known substance or alcohol abuse within the past 2 years.
- •7.Pregnant subjects (ie, a positive or indeterminate pregnancy test) or breastfeeding.
- •8.Females of childbearing potential who are sexually active, and who:
- •1.have not used any of the acceptable contraceptive methods for at least 2 months prior to Day 1.
- •2.refuse to use an acceptable contraceptive method up to 6 weeks after the last dose of TDV or placebo.
- •9.Involved in the trial conduct or their first-degree relatives.
- •10.Subjects identified as an employee of the investigator or trial center, with direct involvement in the proposed trial or other trials under the direction of that investigator or trial center.
- •11.Receipt of previous vaccination against dengue virus.
- •12.Previous participation in any clinical trial of a dengue candidate vaccine, except if it is known that the subject received placebo while participating in those trials.
- •Exclusion Criteria at Vaccination
- •1.Febrile illness (body temperature =38°C [=100.4°F]) or moderate or severe acute illness, or infection, at the time of random assignment
- •2.Medicated with antipyretic and/or analgesic medication(s) within 24 hours prior to TDV or placebo administration
- •3.Any new findings of illness in the interim period since screening Visit 1
研究者
相似试验
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitisMedDRA version: 20.0 Level: PT Classification code 10072579 Term: Granulomatosis with polyangiitis System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0 Level: PT Classification code 10063344 Term: Microscopic polyangiitis System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.1 Level: PT Classification code 10050894 Term: Anti-neutrophil cytoplasmic antibody positive vasculitis System Organ Class: 10021428 - Immune system disordersEUCTR2016-001121-14-CZChemoCentryx, Inc.300
进行中（未招募）
1 期
A study to determinate the safety and efficacy of LY3471851 in Adult Patients with Systemic Lupus ErythematosusMedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2019-003323-38-HUEli Lilly & Company280
进行中（未招募）
1 期
A study to determinate the safety and efficacy of LY3471851 in Adult Patients with Systemic Lupus ErythematosusMedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSystemic Lupus ErythematosusEUCTR2019-003323-38-PLEli Lilly & Company280
进行中（未招募）
不适用
A Study Investigating the Efficacy and Safety of ABT-494 given with Methotrexate in Subjects with Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone.Rheumatoid Arthritis (RA)MedDRA version: 17.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2013-003984-72-ESAbbVie Inc.270
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N–Acetylcysteine in Patients with Idiopathic Pulmonary Fibrosis with Background Treatment of PirfenidonePatients with Idiopathic Pulmonary Fibrosis (IPF)MedDRA version: 17.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2012-000564-14-GBInterMune International AG.122